Rotavirus Vaccines: New Strategies and Approaches

Abstract

Rotaviruses cause an infectious disease that is the main cause of severe diarrhea in children all over the world and one of the factors that determine the level of child mortality. Only live attenuated vaccines are currently used against rotavirus infection. These vaccines are efficient, but a range of side effects, including intussusception risk, is characteristic of them. Complications associated with the use of existing vaccines usually occur in the case of oral administration and develop as the attenuated live vaccines start to replicate in the human intestine. Thus, there is a need for development of modern, efficient, and safe preparations for the prevention of rotavirus infection. These preparations should be incapable of reproduction (replication) in the organism after vaccination. Recombinant vaccines represent a new generation of vaccines against rotavirus infection, and the development and testing of such vaccines, including those intended for parenteral administration, has progressed considerably during recent years. The complex antigenic structure of the rotavirus is one of the problems associated with the production of these vaccines. The present review summarizes published data on genetic and antigenic diversity of rotavirus strains and geographic localization of epidemiologically significant virus variants. The role of capsid proteins in the emergence of immune response against the virus and the current state of research on new candidate recombinant vaccines against rotavirus infection are discussed.